Evidence map›Paper›PMID 41423263›Full record

ArticleJournal for immunotherapy of cancer2025

Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Baojia Qi, Zhaoyu Jiang, Haixia Shen, Jiacheng Li, Zhixiang Wang, Min Fang, Changchun Wang, Youhua Jiang, Jingping Yuan, Inigo Bermejo and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma usingEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Baojia QiZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Zhaoyu JiangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Haixia ShenZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Jiacheng LiDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Zhixiang WangDepartment of Ultrasound, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Min FangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Changchun WangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Youhua JiangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Jingping YuanDepartment of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Inigo BermejoData Science Institute (DSI), Hasselt University, Hasselt, Belgium.
Andre DekkerDepartment of Radiation Oncology (Maastro), GROW Research Institute of Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
Dirk De RuysscherDepartment of Radiation Oncology (Maastro), GROW Research Institute of Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
Leonard WeeDepartment of Radiation Oncology (Maastro), GROW Research Institute of Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
Wencheng ZhangDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.ORCID http://orcid.org/0000-0003-3730-5361
Yongling JiZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China zhen.zhang@maastro.nl jiyl@zjcc.org.cn.
Zhen ZhangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China zhen.zhang@maastro.nl jiyl@zjcc.org.cn.ORCID http://orcid.org/0000-0001-6335-9529

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate preoperative prediction of pathological complete response (pCR) following neoadjuvant chemoimmunotherapy (nCIT) could help individualize treatment for patients with esophageal squamous cell carcinoma (ESCC). This study aimed to develop and externally validate an interpretable multimodal machine learning framework that integrates CT radiomics and H&E-stained whole-slide images pathomics to predict pCR.

methodsIn this multicenter, retrospective study, 335 patients with ESCC who received nCIT followed by esophagectomy were enrolled from three institutions. Patients from one center were divided into a training set (181 patients) and an internal test set (115 patients), while data from the other two centers comprised an external test set (39 patients). We developed unimodal radiomics and pathomics models, and two multimodal fusion models-an intermediate fusion model (MIFM) and a late fusion model (MLFM). Model performance was evaluated using the area under the curve (AUC), accuracy, sensitivity, specificity, and F1 score, with exploratory survival stratification by observed and model-predicted pCR status. Interpretability was treated as a design constraint and operationalized at both the feature and model levels.

resultsThe MIFM outperformed unimodal models and the MLFM across all cohorts, achieving AUC/accuracy/sensitivity/specificity/F1 score of 0.97/0.93/0.84/0.96/0.86 (training set), 0.78/0.87/0.62/0.93/0.63 (internal test set), and 0.76/0.77/0.54/0.88/0.61 (external test set). Both observed and predicted pCR status showed exploratory prognostic stratification for overall survival. Feature definitions were mathematically or morphologically explicit, and case-level/cohort-level explanations together with decision-pathway views provided insights into model reasoning. We additionally provide a user-friendly Graphical User Interface to facilitate clinical practice.

conclusionsWe developed and externally validated an interpretable radiopathomics fusion framework that predicts pCR after nCIT in ESCC using standard-of-care data. This model holds promise as an effective tool for guiding individualized decisions between surveillance and timely surgery.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmunotherapyNeoadjuvant TherapyAgedFemaleHumansMachine LearningMaleMiddle AgedPrognosisRetrospective StudiesComputed tomographyEsophageal CancerPathologic complete response - pCRPathology

Identifiers

PMID41423263
PMCPMC12719895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.